Cytosorbents’ (CTSO) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Cytosorbents (NASDAQ:CTSO) in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a $1.00 target price on the medical research company’s stock. HC Wainwright also issued estimates for Cytosorbents’ Q1 2025 earnings at ($0.02) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at $0.00 EPS and Q4 2025 earnings at $0.00 EPS.

Other research analysts have also issued reports about the company. StockNews.com initiated coverage on Cytosorbents in a report on Wednesday. They issued a hold rating on the stock. EF Hutton Acquisition Co. I raised Cytosorbents to a strong-buy rating in a report on Monday, July 29th. Finally, B. Riley reissued a buy rating and set a $3.00 target price on shares of Cytosorbents in a report on Wednesday, May 15th.

Cytosorbents Stock Performance

Shares of NASDAQ CTSO opened at $0.98 on Wednesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.49 and a quick ratio of 1.21. The stock’s fifty day moving average price is $0.95 and its two-hundred day moving average price is $0.94. Cytosorbents has a one year low of $0.70 and a one year high of $2.95. The firm has a market cap of $53.22 million, a price-to-earnings ratio of -1.66 and a beta of 0.57.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01. Cytosorbents had a negative return on equity of 129.89% and a negative net margin of 75.07%. The firm had revenue of $9.89 million for the quarter, compared to analyst estimates of $9.73 million. During the same period in the prior year, the firm posted ($0.14) EPS. On average, equities analysts forecast that Cytosorbents will post -0.36 EPS for the current year.

Institutional Trading of Cytosorbents

Institutional investors and hedge funds have recently modified their holdings of the business. Key Client Fiduciary Advisors LLC lifted its position in shares of Cytosorbents by 188.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 34,557 shares of the medical research company’s stock worth $33,000 after buying an additional 22,557 shares during the last quarter. Raymond James & Associates bought a new stake in shares of Cytosorbents during the 4th quarter worth $56,000. CM Management LLC raised its position in Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after purchasing an additional 25,000 shares during the last quarter. Sargent Investment Group LLC raised its position in Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock valued at $1,008,000 after purchasing an additional 67,181 shares during the last quarter. Finally, Neuberger Berman Group LLC raised its position in Cytosorbents by 19.9% in the fourth quarter. Neuberger Berman Group LLC now owns 1,801,799 shares of the medical research company’s stock valued at $1,997,000 after purchasing an additional 299,103 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.